As expected, KRAS G12V signaling led to significant decreases in expression of TAP1, TAPBP, as well as HLA-A, HLA-B, HLA-C, and B2M, suggesting that compromised antigen processing and presentation in concert with increases in PD-L1 expression may contribute to an augmented state of immunoresistance in RAS mutant tumor cells. The gene discussed is KRAS; the disease is neoplasm.